Investor mix
10 investors on record; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 8 | 80% |
| Other / undisclosed | 2 | 20% |
Develops ion-channel based drugs for diabetic neuropathy, allergic asthma and pulmonary diseases
10 investors on record; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 8 | 80% |
| Other / undisclosed | 2 | 20% |